Cue Biopharma, Inc. CUE · Stock Open Cue Biopharma, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Cue Biopharma, Inc. Analysis (CUE)
Is Cue Biopharma, Inc. a good investment? Cue Biopharma, Inc. (CUE) is currently trading at 18.66 USD. Market analysts have a consensus price target of 88.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Cue Biopharma, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.48.
Investor FAQ
Does Cue Biopharma, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cue Biopharma, Inc.?
Cue Biopharma, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -29.59.
Company Profile
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| April 24, 2026 | 1:30 |
Community Discussion